4QK Stock Overview
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Codexis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.96 |
| 52 Week High | US$4.23 |
| 52 Week Low | US$1.70 |
| Beta | 2.07 |
| 11 Month Change | 32.42% |
| 3 Month Change | 55.74% |
| 1 Year Change | 126.21% |
| 33 Year Change | -87.85% |
| 5 Year Change | -72.10% |
| Change since IPO | -63.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4QK | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 5.2% | -6.9% | -0.2% |
| 1Y | 126.2% | 1.6% | 7.8% |
Return vs Industry: 4QK exceeded the German Life Sciences industry which returned 1.6% over the past year.
Return vs Market: 4QK exceeded the German Market which returned 7.8% over the past year.
Price Volatility
| 4QK volatility | |
|---|---|
| 4QK Average Weekly Movement | 9.4% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4QK's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4QK's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 174 | Stephen Dilly | www.codexis.com |
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services.
Codexis, Inc. Fundamentals Summary
| 4QK fundamental statistics | |
|---|---|
| Market cap | €326.66m |
| Earnings (TTM) | -€58.65m |
| Revenue (TTM) | €60.87m |
5.4x
P/S Ratio-5.6x
P/E RatioIs 4QK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4QK income statement (TTM) | |
|---|---|
| Revenue | US$64.45m |
| Cost of Revenue | US$60.89m |
| Gross Profit | US$3.55m |
| Other Expenses | US$65.64m |
| Earnings | -US$62.09m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 5.51% |
| Net Profit Margin | -96.35% |
| Debt/Equity Ratio | 39.0% |
How did 4QK perform over the long term?
See historical performance and comparison